We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
VBI Vaccines has commenced enrolment in an adaptive Phase I/II clinical study of its enveloped virus-like particle (eVLP) Covid-19 vaccine candidate, VBI-2902.
Brii Biosciences, a biotech that aims to improve public health in China, launched earlier this year with $260 million in committed capital and a trio of partnerships.....